Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab

Serena Delbue, Mariano Ferraresso, Francesca Elia, Mirco Belingheri, Camilla Carloni, Lucia Signorini, Silvia Carluccio, Simone Dallari, Luciana Ghio, Pasquale Ferrante

Research output: Contribution to journalArticle

Abstract

Rituximab is a chimeric monoclonal antibody reacting with the CD20 antigen on B cells. It has been proposed as treatment for the idiopathic nephrotic syndrome, recurrent idiopathic nephropathy, and focal segmental glomerulosclerosis refractory to steroids. Rituximab influences T-cell immunity and may predispose the patients to opportunistic infections, such as progressive multifocal leukoencephalopathy caused by the polyomavirus JC (JCV). The risk of latent viruses infections/reactivations in pediatric patients receiving monoclonal antibodies is not well known yet. In this longitudinal 6-month study, the effects of rituximab on JCV and BK virus (BKV) replication have been investigated. Blood, serum, and urine samples have been collected monthly from 11 pediatric patients (mean age: 11 years) with the idiopathic nephrotic syndrome and recurrent idiopathic nephropathy, under rituximab therapy. JCV and BKV real-time PCRs and sequencing of the viral protein 1 and the non-coding control region have been conducted. The same investigations have been undertaken on samples collected from eight pediatric patients (controls, mean age: 6 years), with idiopathic nephrotic syndrome or focal segmental glomerulosclerosis, treated with conventional chemotherapy. JCV was detected in the urine of one patient (9%), and one control (12.5%); BKV was found in the urine of 7/11 patients (63.6%) and 2/8 controls (25%) and in blood samples from four patients. No significant difference was found in the mean viral loads and in the viral molecular characterizations between the two groups. The polyomaviruses replication was not associated with rituximab therapy in children. J. Med. Virol. 84:1464-1470, 2012.

Original languageEnglish
Pages (from-to)1464-1470
Number of pages7
JournalJournal of Medical Virology
Volume84
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Polyomavirus
Pediatrics
BK Virus
Focal Segmental Glomerulosclerosis
Urine
CD20 Antigens
Monoclonal Antibodies
JC Virus
Progressive Multifocal Leukoencephalopathy
Opportunistic Infections
Viral Proteins
Virus Diseases
Virus Replication
Rituximab
Viral Load
Real-Time Polymerase Chain Reaction
Immunity
B-Lymphocytes
Therapeutics
Steroids

Keywords

  • Children
  • Monoclonal antibody
  • Nephrotic syndromes
  • Polyomavirus

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab. / Delbue, Serena; Ferraresso, Mariano; Elia, Francesca; Belingheri, Mirco; Carloni, Camilla; Signorini, Lucia; Carluccio, Silvia; Dallari, Simone; Ghio, Luciana; Ferrante, Pasquale.

In: Journal of Medical Virology, Vol. 84, No. 9, 09.2012, p. 1464-1470.

Research output: Contribution to journalArticle

Delbue, S, Ferraresso, M, Elia, F, Belingheri, M, Carloni, C, Signorini, L, Carluccio, S, Dallari, S, Ghio, L & Ferrante, P 2012, 'Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab', Journal of Medical Virology, vol. 84, no. 9, pp. 1464-1470. https://doi.org/10.1002/jmv.23339
Delbue, Serena ; Ferraresso, Mariano ; Elia, Francesca ; Belingheri, Mirco ; Carloni, Camilla ; Signorini, Lucia ; Carluccio, Silvia ; Dallari, Simone ; Ghio, Luciana ; Ferrante, Pasquale. / Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab. In: Journal of Medical Virology. 2012 ; Vol. 84, No. 9. pp. 1464-1470.
@article{63337f78e3c149e5b98be75a71fd040e,
title = "Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab",
abstract = "Rituximab is a chimeric monoclonal antibody reacting with the CD20 antigen on B cells. It has been proposed as treatment for the idiopathic nephrotic syndrome, recurrent idiopathic nephropathy, and focal segmental glomerulosclerosis refractory to steroids. Rituximab influences T-cell immunity and may predispose the patients to opportunistic infections, such as progressive multifocal leukoencephalopathy caused by the polyomavirus JC (JCV). The risk of latent viruses infections/reactivations in pediatric patients receiving monoclonal antibodies is not well known yet. In this longitudinal 6-month study, the effects of rituximab on JCV and BK virus (BKV) replication have been investigated. Blood, serum, and urine samples have been collected monthly from 11 pediatric patients (mean age: 11 years) with the idiopathic nephrotic syndrome and recurrent idiopathic nephropathy, under rituximab therapy. JCV and BKV real-time PCRs and sequencing of the viral protein 1 and the non-coding control region have been conducted. The same investigations have been undertaken on samples collected from eight pediatric patients (controls, mean age: 6 years), with idiopathic nephrotic syndrome or focal segmental glomerulosclerosis, treated with conventional chemotherapy. JCV was detected in the urine of one patient (9{\%}), and one control (12.5{\%}); BKV was found in the urine of 7/11 patients (63.6{\%}) and 2/8 controls (25{\%}) and in blood samples from four patients. No significant difference was found in the mean viral loads and in the viral molecular characterizations between the two groups. The polyomaviruses replication was not associated with rituximab therapy in children. J. Med. Virol. 84:1464-1470, 2012.",
keywords = "Children, Monoclonal antibody, Nephrotic syndromes, Polyomavirus",
author = "Serena Delbue and Mariano Ferraresso and Francesca Elia and Mirco Belingheri and Camilla Carloni and Lucia Signorini and Silvia Carluccio and Simone Dallari and Luciana Ghio and Pasquale Ferrante",
year = "2012",
month = "9",
doi = "10.1002/jmv.23339",
language = "English",
volume = "84",
pages = "1464--1470",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab

AU - Delbue, Serena

AU - Ferraresso, Mariano

AU - Elia, Francesca

AU - Belingheri, Mirco

AU - Carloni, Camilla

AU - Signorini, Lucia

AU - Carluccio, Silvia

AU - Dallari, Simone

AU - Ghio, Luciana

AU - Ferrante, Pasquale

PY - 2012/9

Y1 - 2012/9

N2 - Rituximab is a chimeric monoclonal antibody reacting with the CD20 antigen on B cells. It has been proposed as treatment for the idiopathic nephrotic syndrome, recurrent idiopathic nephropathy, and focal segmental glomerulosclerosis refractory to steroids. Rituximab influences T-cell immunity and may predispose the patients to opportunistic infections, such as progressive multifocal leukoencephalopathy caused by the polyomavirus JC (JCV). The risk of latent viruses infections/reactivations in pediatric patients receiving monoclonal antibodies is not well known yet. In this longitudinal 6-month study, the effects of rituximab on JCV and BK virus (BKV) replication have been investigated. Blood, serum, and urine samples have been collected monthly from 11 pediatric patients (mean age: 11 years) with the idiopathic nephrotic syndrome and recurrent idiopathic nephropathy, under rituximab therapy. JCV and BKV real-time PCRs and sequencing of the viral protein 1 and the non-coding control region have been conducted. The same investigations have been undertaken on samples collected from eight pediatric patients (controls, mean age: 6 years), with idiopathic nephrotic syndrome or focal segmental glomerulosclerosis, treated with conventional chemotherapy. JCV was detected in the urine of one patient (9%), and one control (12.5%); BKV was found in the urine of 7/11 patients (63.6%) and 2/8 controls (25%) and in blood samples from four patients. No significant difference was found in the mean viral loads and in the viral molecular characterizations between the two groups. The polyomaviruses replication was not associated with rituximab therapy in children. J. Med. Virol. 84:1464-1470, 2012.

AB - Rituximab is a chimeric monoclonal antibody reacting with the CD20 antigen on B cells. It has been proposed as treatment for the idiopathic nephrotic syndrome, recurrent idiopathic nephropathy, and focal segmental glomerulosclerosis refractory to steroids. Rituximab influences T-cell immunity and may predispose the patients to opportunistic infections, such as progressive multifocal leukoencephalopathy caused by the polyomavirus JC (JCV). The risk of latent viruses infections/reactivations in pediatric patients receiving monoclonal antibodies is not well known yet. In this longitudinal 6-month study, the effects of rituximab on JCV and BK virus (BKV) replication have been investigated. Blood, serum, and urine samples have been collected monthly from 11 pediatric patients (mean age: 11 years) with the idiopathic nephrotic syndrome and recurrent idiopathic nephropathy, under rituximab therapy. JCV and BKV real-time PCRs and sequencing of the viral protein 1 and the non-coding control region have been conducted. The same investigations have been undertaken on samples collected from eight pediatric patients (controls, mean age: 6 years), with idiopathic nephrotic syndrome or focal segmental glomerulosclerosis, treated with conventional chemotherapy. JCV was detected in the urine of one patient (9%), and one control (12.5%); BKV was found in the urine of 7/11 patients (63.6%) and 2/8 controls (25%) and in blood samples from four patients. No significant difference was found in the mean viral loads and in the viral molecular characterizations between the two groups. The polyomaviruses replication was not associated with rituximab therapy in children. J. Med. Virol. 84:1464-1470, 2012.

KW - Children

KW - Monoclonal antibody

KW - Nephrotic syndromes

KW - Polyomavirus

UR - http://www.scopus.com/inward/record.url?scp=84864147862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864147862&partnerID=8YFLogxK

U2 - 10.1002/jmv.23339

DO - 10.1002/jmv.23339

M3 - Article

C2 - 22825826

AN - SCOPUS:84864147862

VL - 84

SP - 1464

EP - 1470

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 9

ER -